近日,丹纳赫宣布其运营公司Cytiva思拓凡与正序生物达成战略合作,共同开发基于脂质纳米颗粒(LNP)递送系统的基因治疗创新工艺解决方案,推动基因编辑技术治疗遗传性疾病的突破。这也是丹纳赫首次通过其“Danaher Beacon”项目与中国生物技术企业合作。基因遗传性疾病(如镰刀型贫血、β-地中海贫血)种类繁多且多数难治。正序生物开发的高精度、低脱靶单碱基编辑技术,为精准修复致病基因突变提供了可能...
Source Link近日,丹纳赫宣布其运营公司Cytiva思拓凡与正序生物达成战略合作,共同开发基于脂质纳米颗粒(LNP)递送系统的基因治疗创新工艺解决方案,推动基因编辑技术治疗遗传性疾病的突破。这也是丹纳赫首次通过其“Danaher Beacon”项目与中国生物技术企业合作。基因遗传性疾病(如镰刀型贫血、β-地中海贫血)种类繁多且多数难治。正序生物开发的高精度、低脱靶单碱基编辑技术,为精准修复致病基因突变提供了可能...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.